Claims
- 1. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising amino acids 1 to 174 of SEQ ID NO:2; (b) a polynucleotide which is complementary to the polynucleotide of (a); and (c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b).
- 2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
- 3. The polynucleotide of claim 1 wherein the polynucleotide is RNA.
- 4. The polynucleotide of claim 2 comprising nucleotides set forth in SEQ ID NO:1 encoding spsA.
- 5. The polynucleotide of claim 2 comprising spsA coding sequence set forth in SEQ ID NO:1.
- 6. The polynucleotide of claim 2 which encodes a polypeptide comprising amino acid 1 to 174 of SEQ ID NO:2.
- 7. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding the same mature polypeptide expressed by the DNA contained in NCIMB Deposit No. 40771 and having the polynucleotide sequence of SEQ ID NO:1; (b) a polynucleotide complementary to the polynucleotide of (a); and (c) a polynucleotide comprising at least 15 bases of the polynucleotide of (a) or (b).
- 8. A vector comprising the DNA of claim 2.
- 9. A host cell comprising the vector of claim 8.
- 10. A process for producing a polypeptide comprising: expressing from the host cell of claim 9 a polypeptide encoded by said DNA.
- 11. A process for producing a cell which expresses a polypeptide comprising transforming or transfecting the cell with the vector of claim 8 such that the cell expresses the polypeptide encoded by the cDNA contained in the vector.
- 12. A polypeptide comprising an amino acid sequence which is at least 70% identical to amino acid 1 to 174 of SEQ ID NO:2.
- 13. A polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2.
- 14. An antibody against the polypeptide of claim 12.
- 15. An antagonist which inhibits the activity of the polypeptide of claim 12.
- 16. A method for the treatment of an individual having need of spsA comprising: administering to the individual a therapeutically effective amount of the polypeptide of claim 12.
- 17. The method of claim 16 wherein said therapeutically effective amount of the polypeptide is administered by providing to the individual DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 18. A method for the treatment of an individual having need to inhibit spsA polypeptide comprising: administering to the individual a therapeutically effective amount of the antagonist of claim 15.
- 19. A process for diagnosing a disease related to expression of the polypeptide of claim 12 comprising:
determining a nucleic acid sequence encoding said polypeptide.
- 20. A diagnostic process comprising:
analyzing for the presence of the polypeptide of claim 12 in a sample derived from a host.
- 21. A method for identifying compounds which bind to and inhibit an activity of the polypeptide of claim 12 comprising:
contacting a cell expressing on the surface thereof a binding for the polypeptide, said binding being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said binding, with a compound to be screened under conditions to permit binding to the binding; and determining whether the compound binds to and activates or inhibits the binding by detecting the presence or absence of a signal generated from the interaction of the compound with the binding.
- 22. A method for inducing an immunological response in a mammal which comprises inoculating the mammal with spsA, or a fragment or variant thereof, adequate to produce antibody to protect said animal from upper respiratory tract (e.g. otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g. empyema, lung abscess), cardiac (e.g. infective endocarditis), gastrointestinal (e.g. secretory diarrhoea, splenic abscess, retroperitoneal abscess), CNS (e.g. cerebral abscess), eye (e.g. blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal & orbital cellulitis, darcryocystitis), kidney and urinary tract (e.g. epididymitis, intrarenal and perinephric abscess, toxic shock syndrome), skin (e.g. impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis) bone and joint (e.g. septic arthritis, osteomyelitis).
- 23. A method of inducing immunological response in a mammal which comprises, through gene therapy, delivering gene encoding spsA fragment or a variant thereof, for expressing spsA, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody to protect said animal from disease.
- 24. An immunological composition comprising a DNA which codes for and expresses a spsA polynucleotide or protein coded therefrom which, when introduced into a mammal, induces an immunological response in the mammal to a given spsA polynucleotide or protein coded therefrom.
RELATED APPLICATIONS
[0001] This application claims benefit of U.S. patent applications Ser. Nos. 60/027,218, filed Sep. 30, 1996, 60/027,220, filed Oct. 1, 1996, and 60/027,075, filed Sep. 30, 1996.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60027218 |
Sep 1996 |
US |
|
60027220 |
Oct 1996 |
US |
|
60027075 |
Sep 1996 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
08941155 |
Sep 1997 |
US |
Child |
09872047 |
Jun 2001 |
US |